
Madrigal Pharmaceuticals Secures EU Approval for First-Ever MASH Therapy
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced that the European Commission (EC) has granted conditional marketing authorization for Rezdiffra (resmetirom), marking the first approved treatment in the …
Madrigal Pharmaceuticals Secures EU Approval for First-Ever MASH Therapy Read More